Project description
New translational strategy for personalised treatment of type 2 diabetes
Type 2 diabetes (T2D), or adult-onset diabetes, affects hundreds of millions of people worldwide and represents a health problem of enormous proportions. Current treatment strategies are unable to stop disease progression and prevent its devastating complications. Recent studies found that T2D patients can be divided into four clusters suggesting that anti-diabetic treatment should ideally target the underlying pathophysiology of individual patients. The overall goal of the EU-funded TRANSLATIONAL project is to test this approach by tailoring existing and new treatments to patients who are archetypes of the two most severe T2D clusters, those with poor insulin secretion and those with significant insulin resistance. The project aims to study new compounds for personalised treatment including sulforaphane as an early intervention for cases with severe insulin resistance.
Objective
Type 2 diabetes (T2D) is an escalating health problem of enormous proportions. Current treatment strategies are unable to stop disease progression and prevent the devastating complications. Clinical guidelines emphasise the need for personalized treatment. However, this is currently implemented on trial-and-error fashion.
We have recently found that T2D patients can be divided into four clusters, each with different characteristics. This represents a major step forward by pointing out the high variability of the pathophysiology and leads us to propose that anti-diabetic treatment should ideally target the underlying pathophysiology of each patient.
The overall goal is to test this proposition by targeting existing and new treatment to patients who are archetypes of the two most severe T2D clusters, characterised by poor insulin secretion and pronounced insulin resistance, respectively.
As a starting point, we will study how treatment response to existing drugs is influenced by pathophysiological features and also the gut microbiota. Next, we will expand on our recent demonstration that b-cells dedifferentiate in T2D and define the functional and gene expression changes that cause secretory failure. These mechanistic insights will be used to identify new targets for b-cell preservation, which is essential to stop disease progression, in particular in patients with poor secretion. Finally, we will study new compounds for tailored treatment, including sulforaphane as an early intervention for those with severe insulin resistance.
My combined training in cell-physiology, bioinformatics and clinical medicine is unusual but necessary to conduct this multi-disciplinary programme. Whilst the programme builds firmly on my past research, it extends far beyond what I have attempted previously by exploiting novel state-of-the-art methodology to address central metabolic questions of high relevance to understand the causes, management and ultimately prevention of diabetes.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine physiology pathophysiology
- medical and health sciences clinical medicine endocrinology diabetes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-COG - Consolidator Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2019-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
405 30 Goeteborg
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.